RanLOS AB (publ) (”RanLOS” eller ”Bolaget”) utvecklar och säljer en nyckelfärdig lösning inom testni...
Finnair reports Q3 results on Oct 24. We make some downward revisions to our estimates, but note ear...
Redeye provides a brief initial take on Ultimovacs reporting more granular NIPU data.
Redeye endorses Circio’s implementation of the cost reduction program, which will extend its runway.
CMD in Stockholm focused on mesdopetam Potential Ph 3 programme outlined by KOL End-of-phase 2 meeti...
Redeye participated during yesterday’s capital markets day and give an initial comment.
Redeye provides an update on Fantasma Games ahead of its Q3 results (due 8 Nov).
Elanders presented a somewhat soft Q3 2023 report with -11% organic growth, owing to Supply Chain So...
Adj. EBITA SEK 211m (-13% vs. ABGSCe 241m) Consensus EBITA likely to come down by 5-7% 10x 2023e EBI...
Redeye provides an initial comment on the Q3 2023 report from Scandinavian ChemoTech.
Redeye is shocked to learn that one of Alelion's largest customers is refusing to fulfil its part of...
Hansa publishes strong results 5-year after a kidney transplant supported by Idefirix.
Redeye comments on Invisio ahead of its Q3-results (due 25 October) where we expect continued strong...
Ahead of NoHo's Q3 report, we incorporate its latest acquisitions into our estimates.
Order intake likely to start stabilising Healthy balance sheet helpful to gain market share '23e-'25...
We cut '23e-'25e adj. EBITA by 14-5% Negative price/mix from inflation data continues Trading at '23...
Few order announcements put some risk on Q3e sales.
Redeye provides more color on Eniros prelimianary profit announcement.
Redeye is positive about ISAB’s new order worth EUR188,900 from a global generics manufacturer.
Försening i ConfIdes-studien Hansa kom under förra veckan med en bolagsuppdatering.
